Best Healthcare Stocks this April 2026

Incyte Corp. stands out with a remarkable one-year return of 51.67%, demonstrating its strength in oncology and inflammation therapies. Analysts maintain a positive outlook, assigning an "A" rating and a median 12-month price target of $108.50, indicating confidence in its growth potential. With a solid net margin of 25.03%, Incyte is recognized as one of the most profitable firms in its sector, making it an attractive investment for those willing to embrace some volatility.

Incyte Corp has a net margin of 25.03%, indicating it is one of the more profitable companies in its industry.

Investors who are uncomfortable with high uncertainty and volatility should avoid Incyte, as it carries significant downside risk despite potential for growth.

Incyte's revenue and earnings are expected to decline by 1.4% and 13.8% per year, respectively, with EPS projected to decrease by 14.7% annually over the next three years.

AbbVie Inc. presents a compelling opportunity for investors, primarily due to the robust revenue generated from its immunology drugs, Skyrizi and Rinvoq, which underpins a potential upside of 20%. With an attractive dividend yield of 3.19% and impressive 5-year returns of 98.13%, this stock is ideal for those seeking both growth and reliable income. Analysts have a median 12-month price target of $258.00, reflecting a positive outlook, with ratings ranging from Overweight to Buy from respected firms.

Assuming an average annual growth rate of 9%, AbbVie stock could reach a market capitalization of approximately $600 billion in five years.

Gilead Sciences stands out as a compelling investment with a solid one-year return of 23.43% and an impressive five-year return of 107.29%. Analysts are optimistic, rating the stock as a Strong Buy, with a median price target of $158.86, suggesting potential upside. The company’s promising pipeline in antivirals and oncology further enhances its appeal for investors seeking growth in innovative healthcare solutions.

Gilead Sciences has a consensus rating of Strong Buy, with a price target of $158.00, indicating a potential upside of 13.1%.

The average price target for Gilead Sciences is $158.86, with estimates ranging from $118.00 to $180.00, suggesting a potential increase of 14.9% from its last closing price of $138.26.

An attractive option for investors seeking stability and growth, Johnson & Johnson boasts a robust portfolio in pharmaceuticals and medical devices. With a solid 1-year return of 47.94% and a 5-year return of 45.34%, it also offers a dividend yield of 2.11%. Analysts are optimistic, setting a median 12-month price target of $220, reflecting strong confidence in its long-term performance through 2026.

The highest closing price for Johnson & Johnson stock was $248.56 on March 2, 2026, while the 52-week high is $251.71.

Warren Buffett first traded Johnson & Johnson stock in Q1 2006, buying shares twelve times and selling them ten times, ultimately selling his entire stake between Q2 2012 and Q3 2023.

JNJ stock is facing challenges due to legal uncertainties, revenue loss from drug exclusivity expirations, MedTech headwinds, and broader market volatility.

Moderna Inc. stands out as a top-performing healthcare stock, boasting a remarkable one-year return of 64.38%, fueled by its innovative biotech advancements. Analysts currently rate the stock as a Hold, with a median 12-month price target of $35.00, suggesting cautious optimism among market experts. While recent performance shows significant volatility with a five-year return of -57.22%, the company's ongoing developments in biotechnology may offer potential upside for investors looking for growth opportunities.

Moderna (MRNA) has a consensus rating of Hold from 12 analysts, with 0% recommending Strong Buy, 8% Buy, 67% Hold, 25% Sell, and 0% Strong Sell.

The average 12-month price target for MRNA, based on 18 analysts, is $36.13, with a high of $69.00 and a low of $12.00, indicating a potential decline of 29.68% from its last price of $51.38.

Cardinal Health, Inc. stands out as a solid investment option, boasting a remarkable 51.47% return over the past year and an impressive 231.39% over five years, indicating strong growth potential. With a dividend yield of nearly 1%, the company has consistently delivered dividends for 29 years, showcasing its commitment to reliable income for investors. Analysts maintain a consensus Buy rating, with a median price target of $256, reflecting confidence in its distribution and supply chain strengths.

Cardinal Health (CAH) has a consensus rating of Buy from 12 analysts, with 33% recommending Strong Buy, 58% recommending Buy, and no analysts suggesting Sell.

Cardinal Health's stock price has decreased by $0.95 (0.45%) to $210.92, but it has risen by $1.00 in pre-market trading.

CAH has increased its dividend for 29 consecutive years, with a 5-year average annual increase of 1.02%, currently paying out 29.35% of earnings as dividends.

The average twelve-month price target for Cardinal Health is $245.67, indicating a potential upside of 18.16% from its current price of $207.91.

CVS Health is regaining momentum in the health insurance sector, with an expected 7.5% earnings growth by 2026. Currently, the company's dividend yield stands at 3.74%, providing a reliable income stream for investors. Analysts maintain a positive outlook, with a median 12-month price target of $93 and strong ratings from firms such as Bernstein and B of A Securities.

CVS Health Corporation is currently trading in the middle of its 52-week range and has dropped 1.04% to $71.74, which is below its 200-day moving average.

CVS reported total revenue of $105.7 billion, an 8.2% increase from the previous year, and a record annual revenue of $402.1 billion, up 7.8% year over year.

Analysts have set an average price target of $95.05 for CVS Health, with a forecasted upside of 32.49% from its current price of $71.74.

Warren Buffett initially invested in CVS Health in Q3 2011 but sold all his shares by Q3 2012 and no longer owns any.

Eli Lilly & Co. is a standout pick for 2026, particularly with its promising growth in diabetes and obesity drugs such as Zepbound, which will soon benefit from Medicare deals starting in April 2026. With a robust 5-year return of 378.65% and a current dividend yield of 0.60%, this stock presents an attractive option for long-term investors. Analysts are optimistic, with a median 12-month price target of $1,280, signaling potential for continued growth despite recent mixed ratings from major firms.

Eli Lilly's earnings estimates for 2026 and 2027 have improved recently, and it currently has a Zacks Rank of #3 (Hold), indicating it may be a reasonable long-term investment.